Somatorelin - ICN

Drug Profile

Somatorelin - ICN

Alternative Names: GRF 1-44; Growth hormone releasing factor (1-44); Somatoliberin

Latest Information Update: 03 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fujisawa
  • Developer Roche; Valeant Pharmaceuticals International
  • Class Amino acids; Hormones; Peptides
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Muscular atrophy; Somatotropin deficiency

Most Recent Events

  • 15 Feb 1999 Phase-I clinical trials for Muscle wasting in Switzerland (Implant)
  • 13 Nov 1997 Phase-II clinical trials for Muscle wasting in Yugoslavia (Parenteral)
  • 09 Jul 1997 Phase-III clinical trials for Somatotropin deficiency in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top